

Where Are We with Clinical Trials for Alzheimer's Disease? Where are you?


Tiffany Chow, MD, MSc, FAAN,
FANPA

Professor, USC Clinical Neurology
& Medical Director, USC ATRI

Keck School of Medicine of **USC**
Alzheimer's Therapeutic Research Institute



Converging -omics & Systems Biology



Achievements & Disappointments

- Most recent FDA-approved medication was memantine (2003)
- CNS drug development fails for 90% of candidates
- Pharmaceutical companies have been subsumed, re-arranged
- Anti-amyloid agents have not shown adequate signal in patients who already have AD

What we're doing at ATRI

- Tracking the biomarkers (ADNI, LEADS)
 - Imaging
 - CSF
 - Blood
- Testing interventions
 - Already with AD
 - More vulnerable to starting memory loss due to AD

Trials for people with MCI or AD

- Will an anti-cancer agent work to control abnormal protein manufacture?



- Intranasal insulin



- Nicotine patch



Prevention Trials

- A4 – solanezumab



- EARLY – BACE inhibitor



Did You Know?

- There are registries available to help you get involved with the right clinical trial at the right time
- Cognitive reserve is still high on our list for prevention of AD
- Much of what increases your risk of AD is under your control!
- Physical activity effective for staving off change